NKTR Investors Have Opportunity to Lead Nektar Therapeutics Securities Fraud Lawsuit with the Schall Law Firm

Core Viewpoint - Nektar Therapeutics is facing a class action lawsuit for securities fraud due to alleged false and misleading statements regarding its clinical trial for the product candidate rezpegaldesleukin [1] Summary by Relevant Sections Class Action Lawsuit - The Schall Law Firm is reminding investors of a class action lawsuit against Nektar Therapeutics for violations of the Securities Exchange Act of 1934 [1] - Investors who purchased Nektar's securities between February 26, 2025, and December 15, 2025, are encouraged to contact the firm before May 5, 2026 [1] Allegations Against Nektar - The complaint alleges that Nektar made false and misleading statements about the integrity of its REZOLVE-AA trial [1] - Issues with patient enrollment for the REZOLVE-AA trial are claimed to have deviated from protocol standards, potentially impacting trial findings negatively [1] - The company's public statements were deemed false and materially misleading throughout the class period, leading to investor damages when the truth was revealed [1]